Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Enterprise Value (2016 - 2025)

CorMedix (CRMD) has disclosed Enterprise Value for 14 consecutive years, with -$155.2 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 200.27% to -$155.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$155.2 million through Dec 2025, down 200.27% year-over-year, with the annual reading at -$155.2 million for FY2025, 200.27% down from the prior year.
  • Enterprise Value hit -$155.2 million in Q4 2025 for CorMedix, down from -$55.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$19.8 million in Q2 2023 to a low of -$190.7 million in Q2 2025.
  • Historically, Enterprise Value has averaged -$67.5 million across 5 years, with a median of -$55.7 million in 2025.
  • Biggest five-year swings in Enterprise Value: crashed 342.79% in 2021 and later soared 68.91% in 2022.
  • Year by year, Enterprise Value stood at -$53.4 million in 2021, then increased by 19.04% to -$43.3 million in 2022, then crashed by 100.1% to -$86.6 million in 2023, then soared by 40.31% to -$51.7 million in 2024, then crashed by 200.27% to -$155.2 million in 2025.
  • Business Quant data shows Enterprise Value for CRMD at -$155.2 million in Q4 2025, -$55.7 million in Q3 2025, and -$190.7 million in Q2 2025.